JP2015517524A - （４Ｓ，４ａＳ，５ａＲ，１２ａＳ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの使用方法 - Google Patents

（４Ｓ，４ａＳ，５ａＲ，１２ａＳ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの使用方法 Download PDF

Info

Publication number
JP2015517524A
JP2015517524A JP2015512752A JP2015512752A JP2015517524A JP 2015517524 A JP2015517524 A JP 2015517524A JP 2015512752 A JP2015512752 A JP 2015512752A JP 2015512752 A JP2015512752 A JP 2015512752A JP 2015517524 A JP2015517524 A JP 2015517524A
Authority
JP
Japan
Prior art keywords
methyl
crystalline
salt
naphthacene
tetrahydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517524A5 (enExample
Inventor
コールター，キャサリン
ジョンストン，ショーン，エム．
セイェディ，ファルザネー
デブリーズ，ティナ，エム．
Original Assignee
パラテック ファーマシューティカルズ インコーポレイテッド
パラテック ファーマシューティカルズ インコーポレイテッド
ワーナー・チルコット・カンパニー・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パラテック ファーマシューティカルズ インコーポレイテッド, パラテック ファーマシューティカルズ インコーポレイテッド, ワーナー・チルコット・カンパニー・エルエルシー filed Critical パラテック ファーマシューティカルズ インコーポレイテッド
Publication of JP2015517524A publication Critical patent/JP2015517524A/ja
Publication of JP2015517524A5 publication Critical patent/JP2015517524A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015512752A 2012-05-14 2013-05-14 （４Ｓ，４ａＳ，５ａＲ，１２ａＳ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの使用方法 Pending JP2015517524A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261646754P 2012-05-14 2012-05-14
US61/646,754 2012-05-14
PCT/US2013/040933 WO2013173326A1 (en) 2012-05-14 2013-05-14 Methods of using (4s,4as,5ar,12as)-4- dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide

Publications (2)

Publication Number Publication Date
JP2015517524A true JP2015517524A (ja) 2015-06-22
JP2015517524A5 JP2015517524A5 (enExample) 2016-06-30

Family

ID=49548796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512752A Pending JP2015517524A (ja) 2012-05-14 2013-05-14 （４Ｓ，４ａＳ，５ａＲ，１２ａＳ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの使用方法

Country Status (6)

Country Link
US (1) US20130302442A1 (enExample)
EP (1) EP2849757A4 (enExample)
JP (1) JP2015517524A (enExample)
AU (1) AU2013262991A1 (enExample)
CA (1) CA2873412A1 (enExample)
WO (1) WO2013173326A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012155146A1 (en) * 2011-05-12 2012-11-15 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
EP4268897A3 (en) * 2015-03-24 2024-01-03 Paratek Pharmaceuticals, Inc. Minocycline compounds for biodefense
US12297161B2 (en) * 2018-04-06 2025-05-13 Almirall, Llc Process for making sarecycline hydrochloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines
JP2007524693A (ja) * 2004-02-20 2007-08-30 ザ バーナム インスティチュート 抗菌性の糖質及びそれを用いた方法
JP2010513527A (ja) * 2006-12-21 2010-04-30 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
WO2011025982A2 (en) * 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2012021829A1 (en) * 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Methods of treating bacterial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007338681B2 (en) * 2006-12-21 2013-09-26 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
WO2012155146A1 (en) * 2011-05-12 2012-11-15 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375068A1 (en) * 1988-12-23 1990-06-27 Gist-Brocades N.V. Combining bismuth compounds and tetracyclines
JP2007524693A (ja) * 2004-02-20 2007-08-30 ザ バーナム インスティチュート 抗菌性の糖質及びそれを用いた方法
JP2010513527A (ja) * 2006-12-21 2010-04-30 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
WO2011025982A2 (en) * 2009-08-28 2011-03-03 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
WO2012021829A1 (en) * 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Methods of treating bacterial infections

Also Published As

Publication number Publication date
EP2849757A1 (en) 2015-03-25
US20130302442A1 (en) 2013-11-14
AU2013262991A1 (en) 2014-12-04
WO2013173326A1 (en) 2013-11-21
CA2873412A1 (en) 2013-11-21
EP2849757A4 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
JP6876082B2 (ja) （４ｓ，４ａｓ，５ａｒ，１２ａｓ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの結晶塩及びそれを使用する方法
US9302012B2 (en) Anti-bacterial siderophore-aminopenicillin conjugates
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
JP2011528354A (ja) 抗生物質
JP2015517524A (ja) （４Ｓ，４ａＳ，５ａＲ，１２ａＳ）−４−ジメチルアミノ−３，１０，１２，１２ａ−テトラヒドロキシ−７−［（メトキシ（メチル）アミノ）−メチル］−１，１１−ジオキソ−１，４，４ａ，５，５ａ，６，１１，１２ａ−オクタヒドロ−ナフタセン−２−カルボン酸アミドの使用方法
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
WO2015061630A2 (en) Reduction-triggered antibacterial sideromycins
US9862680B2 (en) Peripherally substituted monocyclic beta-lactams
US10717757B2 (en) Ketolides having antibacterial activity
KR20030027094A (ko) 신규 에스테르 또는 아미드 유도체
US10888566B1 (en) Chemosensitization of resistant Pseudomonas aeruginosa by synthetically related compounds
WO2019190354A1 (ru) Производные фенил формамидина, обладающие антимикобактериальной активностью
CN111662351B (zh) 新奥克梯隆型皂苷元衍生物及制备抗耐药菌药物应用
HK1194659B (en) Crystalline salts of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same
JP2014503578A (ja) Ｍｄｒポンプ阻害活性を有する新規なアザクマリン誘導体

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171003